PharmaTher Receives US FDA Approval Goal Date for Ketamine
Portfolio Pulse from
PharmaTher Holdings Ltd. has received an Amendment Acknowledgement Letter from the FDA for its New Drug Application for Ketamine, marking a significant step in the drug's commercialization process.
March 11, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmaTher Holdings Ltd. received an FDA Amendment Acknowledgement for its Ketamine New Drug Application, indicating progress in its regulatory approval process.
The FDA's Amendment Acknowledgement for PharmaTher's Ketamine NDA is a positive regulatory development, likely boosting investor confidence and potentially increasing the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100